Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats

Amir H. Rezvani, Ehsan Kholdebarin, Frederic H. Brucato, Patrick M. Callahan, David A. Lowe, Edward D. Levin

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

It is well established that nicotinic systems in the brain are critically involved in attentional processes in both animals and humans. The current study assessed the effects of a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist, R3487/MEM3454 (also referred to as R3487 or MEM 3454) on sustained attention in rats performing an operant visual signal detection task. The effects of R3487/MEM3454 were compared to those of the acetylcholinesterase inhibitor/nicotinic α7 allosteric positive modulator galanthamine. Adult female Sprague-Dawley rats were injected subcutaneously with R3487/MEM3454 (0.03, 0.1, 0.15, 0.3 and 0.6 mg/kg), galanthamine (0.25, 0.5, 1, 2 mg/kg) or vehicle 30 min before the attentional test. In the second study, the time-dependent effects of R3487/MEM3454 were assessed by injecting the compound (0.6 mg/kg, s.c.) at different pretreatment intervals (30, 60 or 90 min) before the start of the attentional task. Our results show a significant dose-effect for R3487/MEM3454 on percent hit accuracy performance without any significant alteration on percent correct rejection performance. In the time-dependent test, R3487/MEM3454 significantly increased the percent hit accuracy performance when animals were injected 60 min before the start of the attentional task. Administration of galanthamine failed to significantly increase percent hit accuracy performance and increasing the dose of galanthamine produced a decrease in percent correct rejection performance. The present findings with R3487/MEM3454 suggest that nicotinic α7 receptors and/or 5-HT3 receptors may play an important role in modulating sustained attention and that R3487/MEM3454 may have therapeutic potential in improving sustained attention in humans.

Original languageEnglish (US)
Pages (from-to)269-275
Number of pages7
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume33
Issue number2
DOIs
StatePublished - Mar 17 2009

Fingerprint

Galantamine
Serotonin 5-HT3 Receptor Antagonists
Nicotinic Receptors
Receptors, Serotonin, 5-HT3
Cholinesterase Inhibitors
Sprague Dawley Rats
Brain

Keywords

  • Adult ADHD
  • Cognition
  • Galanthamine
  • MEM 3454
  • Schizophrenia
  • Signal detection task

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. / Rezvani, Amir H.; Kholdebarin, Ehsan; Brucato, Frederic H.; Callahan, Patrick M.; Lowe, David A.; Levin, Edward D.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 33, No. 2, 17.03.2009, p. 269-275.

Research output: Contribution to journalArticle

Rezvani, Amir H. ; Kholdebarin, Ehsan ; Brucato, Frederic H. ; Callahan, Patrick M. ; Lowe, David A. ; Levin, Edward D. / Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009 ; Vol. 33, No. 2. pp. 269-275.
@article{a157b9ce448b4ca5b4c99331c3d998be,
title = "Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats",
abstract = "It is well established that nicotinic systems in the brain are critically involved in attentional processes in both animals and humans. The current study assessed the effects of a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist, R3487/MEM3454 (also referred to as R3487 or MEM 3454) on sustained attention in rats performing an operant visual signal detection task. The effects of R3487/MEM3454 were compared to those of the acetylcholinesterase inhibitor/nicotinic α7 allosteric positive modulator galanthamine. Adult female Sprague-Dawley rats were injected subcutaneously with R3487/MEM3454 (0.03, 0.1, 0.15, 0.3 and 0.6 mg/kg), galanthamine (0.25, 0.5, 1, 2 mg/kg) or vehicle 30 min before the attentional test. In the second study, the time-dependent effects of R3487/MEM3454 were assessed by injecting the compound (0.6 mg/kg, s.c.) at different pretreatment intervals (30, 60 or 90 min) before the start of the attentional task. Our results show a significant dose-effect for R3487/MEM3454 on percent hit accuracy performance without any significant alteration on percent correct rejection performance. In the time-dependent test, R3487/MEM3454 significantly increased the percent hit accuracy performance when animals were injected 60 min before the start of the attentional task. Administration of galanthamine failed to significantly increase percent hit accuracy performance and increasing the dose of galanthamine produced a decrease in percent correct rejection performance. The present findings with R3487/MEM3454 suggest that nicotinic α7 receptors and/or 5-HT3 receptors may play an important role in modulating sustained attention and that R3487/MEM3454 may have therapeutic potential in improving sustained attention in humans.",
keywords = "Adult ADHD, Cognition, Galanthamine, MEM 3454, Schizophrenia, Signal detection task",
author = "Rezvani, {Amir H.} and Ehsan Kholdebarin and Brucato, {Frederic H.} and Callahan, {Patrick M.} and Lowe, {David A.} and Levin, {Edward D.}",
year = "2009",
month = "3",
day = "17",
doi = "10.1016/j.pnpbp.2008.11.018",
language = "English (US)",
volume = "33",
pages = "269--275",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats

AU - Rezvani, Amir H.

AU - Kholdebarin, Ehsan

AU - Brucato, Frederic H.

AU - Callahan, Patrick M.

AU - Lowe, David A.

AU - Levin, Edward D.

PY - 2009/3/17

Y1 - 2009/3/17

N2 - It is well established that nicotinic systems in the brain are critically involved in attentional processes in both animals and humans. The current study assessed the effects of a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist, R3487/MEM3454 (also referred to as R3487 or MEM 3454) on sustained attention in rats performing an operant visual signal detection task. The effects of R3487/MEM3454 were compared to those of the acetylcholinesterase inhibitor/nicotinic α7 allosteric positive modulator galanthamine. Adult female Sprague-Dawley rats were injected subcutaneously with R3487/MEM3454 (0.03, 0.1, 0.15, 0.3 and 0.6 mg/kg), galanthamine (0.25, 0.5, 1, 2 mg/kg) or vehicle 30 min before the attentional test. In the second study, the time-dependent effects of R3487/MEM3454 were assessed by injecting the compound (0.6 mg/kg, s.c.) at different pretreatment intervals (30, 60 or 90 min) before the start of the attentional task. Our results show a significant dose-effect for R3487/MEM3454 on percent hit accuracy performance without any significant alteration on percent correct rejection performance. In the time-dependent test, R3487/MEM3454 significantly increased the percent hit accuracy performance when animals were injected 60 min before the start of the attentional task. Administration of galanthamine failed to significantly increase percent hit accuracy performance and increasing the dose of galanthamine produced a decrease in percent correct rejection performance. The present findings with R3487/MEM3454 suggest that nicotinic α7 receptors and/or 5-HT3 receptors may play an important role in modulating sustained attention and that R3487/MEM3454 may have therapeutic potential in improving sustained attention in humans.

AB - It is well established that nicotinic systems in the brain are critically involved in attentional processes in both animals and humans. The current study assessed the effects of a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist, R3487/MEM3454 (also referred to as R3487 or MEM 3454) on sustained attention in rats performing an operant visual signal detection task. The effects of R3487/MEM3454 were compared to those of the acetylcholinesterase inhibitor/nicotinic α7 allosteric positive modulator galanthamine. Adult female Sprague-Dawley rats were injected subcutaneously with R3487/MEM3454 (0.03, 0.1, 0.15, 0.3 and 0.6 mg/kg), galanthamine (0.25, 0.5, 1, 2 mg/kg) or vehicle 30 min before the attentional test. In the second study, the time-dependent effects of R3487/MEM3454 were assessed by injecting the compound (0.6 mg/kg, s.c.) at different pretreatment intervals (30, 60 or 90 min) before the start of the attentional task. Our results show a significant dose-effect for R3487/MEM3454 on percent hit accuracy performance without any significant alteration on percent correct rejection performance. In the time-dependent test, R3487/MEM3454 significantly increased the percent hit accuracy performance when animals were injected 60 min before the start of the attentional task. Administration of galanthamine failed to significantly increase percent hit accuracy performance and increasing the dose of galanthamine produced a decrease in percent correct rejection performance. The present findings with R3487/MEM3454 suggest that nicotinic α7 receptors and/or 5-HT3 receptors may play an important role in modulating sustained attention and that R3487/MEM3454 may have therapeutic potential in improving sustained attention in humans.

KW - Adult ADHD

KW - Cognition

KW - Galanthamine

KW - MEM 3454

KW - Schizophrenia

KW - Signal detection task

UR - http://www.scopus.com/inward/record.url?scp=60049101441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60049101441&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2008.11.018

DO - 10.1016/j.pnpbp.2008.11.018

M3 - Article

C2 - 19110025

AN - SCOPUS:60049101441

VL - 33

SP - 269

EP - 275

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 2

ER -